Pharmacokinetic profiles determine optimal combination treatment schedules in computational models of drug resistance

Keyphrases

• BT-20 50%
• Combination Therapeutic Strategy 50%
• Combination Treatment 100%
• Computational Model 100%
• Computational Modeling 50%
• Drug Administration 50%
• Drug Combination 50%
• Drug Interactions 50%
• Drug Pharmacokinetics 50%
• Drug Resistance 100%
• Erlotinib 50%
• In Vitro Data 50%
• Interaction Curves 50%
• Interaction Effect 50%
• Misspecification 50%
• Modeling Platform 50%
• Modeling Software 50%
• Multidrug 50%
• Non-small Cell Lung Cancer Cells 50%
• Optimal Combination 100%
• Optimal Schedule 50%
• Pharmacokinetic Drug Interactions 50%
• Pharmacokinetic Profile 100%
• Pharmacokinetic/pharmacodynamic Relationship 50%
• Pharmacokinetics 50%
• Publicly Available 100%
• Resistant Cells 50%
• Treatment Schedule 100%
• Triple-negative Breast Cancer Cells 50%
• Tumor Growth 50%
• Tyrosine Kinase Inhibitor 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Drug 20%
• Drug Administration 20%
• Drug Interaction 40%
• Drug Resistance 100%
• Elimination 20%
• Erlotinib 20%
• Non Small Cell Lung Cancer 20%
• Pharmacodynamics 20%
• Pharmacokinetics 100%
• Protein Tyrosine Kinase Inhibitor 20%
• Triple Negative Breast Cancer 20%
• Tumor Growth 20%